Business Description
Racura Oncology Ltd is an Australian biopharmaceutical company focused on developing treatments for cancer. Its lead drug, RC220, works by targeting specific structures in cancer cells to block a key protein that drives tumor growth, and is currently being tested in late-stage clinical trials for blood cancer as well as earlier-stage trials for lung cancer and in combination with another cancer treatment. The company works alongside a number of respected research institutions and medical centers to advance its programs. Founded in 2011 and based in Sydney, Racura Oncology was previously known as Race Oncology Ltd before changing its name in late 2025.
